|
Sub-category:
Autologous Bone Marrow Transplantation
Category:
Bone Marrow Transplantation
Meeting:
2001 ASCO Annual Meeting
Abstract No:
1757
Citation:
Proc Am Soc Clin Oncol 20: 2001 (abstr 1757)
Author(s):
Alejandro Restrepo, P. Devore, J. Alexander, M. Takemoto, C. Encarnacion, M. Wholey, T. Tsai, N. S. Callander, J. E. Anderson, H. Ferrao, D. Postoak, E. Gokmen, T. Walsh, D. Schneider, G. Padayao, C. Thompson, J. Joseph, B. Neumon, G. West, M. Restrepo, J. Patterson, C. O. Freytes, University of Texas Health Science Center, San Antonio, TX.
Abstract:
In many institutions, two different VAD are utilized in patients undergoing APBSCT, one for leukopheresis and one for support duing the tranplant period. This results in pt discomfort and increased cost since two VAD have to be inserted. We have utilized a central venous triple-lumen silicone long-term access catheter for leukopheresis and transplant support (Neostar[reg], Pherese-flow[reg]). This VAD delivers adequate flow rates for leukopheresis and is also suitable for chemotherapy and fluid infusions. The purpose of this study was to analyze the complication rate of this VAD during leukopheresis and transplantation. We prospecively analyzed 67 consecutive pts who underwent leukopheresis and ABPSCT between January 1999 and October 2000. The median age was 54 (22-74) and 92% were men. There were no complications related to catheter insertion. The median number of pheresis performed with this VAD was 2 (range 1-11). The median duration of insertion was 33 days (range 12-112). Fifty-nine pts had fever (88%). Of those, 22 pts had at least one positive blood culture (33%) and 14 pts had positive blood cultures from both peripheral blood and VAD. Common microorganisms cultured from blood were staphylococcus coagulase negative (12 pts), pseudomone aeruginosa (5 pts), and staphylococcus aureus (2 pts). Twenty-two pts (31%) experienced catheter occlusion or thrombosis. They were treated with heparin (12 pts), urokinase or tPA (4 pts). Reasons for removal of the catheter included: completion of treatment in 53 pts (79%), infection or suspected infection in 11 pts (16%), two catheters were accidentally pulled by the pts (3%) and one catheter was removed because of tear in one of the ports (<2%). Only 10 pts (15%) required insertion of another VAD to complete treatement related to APBSCT. We conclude that the infectious and thrombotic complication rate of this VAD is acceptable in patients undergoing APBSCT allowing the majority of patients to undergo leukopheresis and transplantation with a single VAD.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by Alejandro Restrepo:
Presentations by Alejandro Restrepo:
Educational Book Manuscripts by Alejandro Restrepo:
|
